Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation

The Lancet

9 February 2023 - As antibiotic resistance increases globally, antibiotic innovation is struggling. The WHO states that the antibiotic clinical pipeline is “insufficient to tackle the challenge of increasing emergence and spread of antimicrobial resistance”. 

To prevent the development of resistance, new antibiotics are used as last resort treatments and, if properly used, have small patient populations, resulting in fairly low sales revenues for industry.

Read The Lancet article (subscription required)

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Development